Acer Therapeutics Inc
ACER
ACER was delisted on the 8th of November, 2023.
40 hedge funds and large institutions have $8.34M invested in Acer Therapeutics Inc in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 8 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
8% more funds holding
Funds holding: 37 → 40 (+3)
13% less capital invested
Capital invested by funds: $9.6M → $8.34M (-$1.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$335K |
| 2 |
BlackRock
New York
|
+$202K |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$179K |
| 4 |
JGC
J. Goldman & Co
New York
|
+$155K |
| 5 |
State Street
Boston,
Massachusetts
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$430K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$318K |
| 3 |
VF
Virtu Financial
New York
|
-$111K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$94K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$67K |
ACER Hedge Fund Activity: Q3 2019 in Review
40 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Acer Therapeutics Inc (ACER) for Q3 2019, worth a combined $8.34M — down 13% from $9.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ACER positions and 8 closed out — a net gain of 3 holders — while 14 added to existing stakes and 10 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $335K. The largest seller was Raymond James & Associates, cutting an estimated $430K.
- 40 institutional investors held Acer Therapeutics Inc (ACER) as of Q3 2019, up from 37 in Q2 2019.
- Funds reported $8.34M of Acer Therapeutics Inc stock for Q3 2019, down 13% quarter-over-quarter.
- 11 funds opened new Acer Therapeutics Inc positions in Q3 2019 and 8 closed out, a net change of +3 holders.
- The largest Acer Therapeutics Inc buyer in Q3 2019 was Stonepine Capital Management, an estimated $335K added.
- The largest Acer Therapeutics Inc seller in Q3 2019 was Raymond James & Associates, an estimated $430K sold.
Based on aggregated 13F filings for Q3 2019.